FDA Lays Out Weight of Evidence Guidelines for Fetal Toxicity in Oncology

Drug Industry Daily
A A
Cancer drug sponsors won’t have to do separate studies if they can demonstrate that the weight of evidence shows that a given drug is dangerous to developing babies, the FDA says in a final guidance document issued Thursday.

To View This Article:

Login

Subscribe To Drug Industry Daily